The biotech news you missed from the weekend
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: Pharmaceuticals
STAT+: The prices of 8 drugs were hiked without proof of new benefits, costing the U.S. $1.2 billion in 2022, report finds
During 2022, drugmakers substantially raised prices on eight widely used medicines without any new clinical…
STAT+: Amid fears of superbugs, sales of antibiotics used in food-producing livestock rose last year
Amid fears of superbugs, the sale of medically important antibiotics given to food-producing livestock rose…
STAT+: Vertex gets a win as Colorado board leaves cystic fibrosis drug off a list of unaffordable medicines
In a win for Vertex Pharmaceuticals, a Colorado state board voted not to place the…
CRISPR is about to make history. Here’s the 5-minute rundown of what to expect
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biden proposal targeting pharma patents spurs industry fears and consumer doubts
Will this be a half a loaf? After months of deliberation, the Biden administration on…
Diabetes ‘epidemic’ gets a Senate hearing
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Eli Lilly’s latest $1.4 billion deal might come unglued
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices
In 1997, Celgene obtained a key patent for what would become a blockbuster blood cancer…
Sanofi says it has 12 blockbusters in its back pocket. Will investors believe it?
NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their…
.jpg)
STAT+: To lower drug prices, White House takes new aim at pharma patents
WASHINGTON — The White House is throwing its support behind a controversial authority that allows…
Most drugmakers have so far ignored looming FTC deadline to withdraw or amend wayward patents
With 10 days to go, only one company has responded to a demand by the…
STAT+: U.S. judge orders Minnesota to pause its drug pricing transparency law over constitutional issues
In a victory for the pharmaceutical industry, a U.S. judge ruled that Minnesota must temporarily…
Why Cerevel Therapeutics has risen 50% in three days without changing anything
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pfizer plans to depart BIO
WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources…
STAT+: CVS’s new drug payment plan won’t lower patients’ prices, experts warn
CVS Health is promising to simplify how its pharmacies get paid for drugs. But that…
STAT+: Senate panel considers Medicare policy fixes to drug shortages
WASHINGTON — Members of the Senate Finance Committee took their first steps today toward using…
STAT+: $100 billion estimate for Ozempic-style weight loss drugs gets wary eye from analysts
NEW YORK — Will the world actually soon spend $100 billion a year on the…
STAT Morning Rounds: The health news you need to read today
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
Carmot’s chance of beating the odds in the biotech market just ended
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: BIO selects rare disease advocate, biotech executive John Crowley as new CEO
WASHINGTON — The Biotechnology Innovation Organization has chosen longtime biotech executive and rare disease advocate John…
STAT+: J&J to emphasize cancer drugs and stop much of its vaccine research
Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis…
STAT+: FDA efforts to oversee foreign drug manufacturing remain inadequate to ensure safety, analysis finds
In the wake of the Covid-19 pandemic, the Food and Drug Administration inspected far fewer…
.jpg)
STAT Morning Rounds: Six health news stories you need to start your day
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
Novartis is building a new radioligand plant in China
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: How sickle cell became the first disease treated by CRISPR
Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of…
STAT+: Roche to acquire obesity-focused Carmot Therapeutics for $2.7 billion
LONDON — The booming obesity market is attracting another player, as pharma giant Roche said…
Johnson & Johnson bets heavy on AI-driven drug discovery
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial
Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after…
STAT+: Texas AG accuses Pfizer of ‘intentionally’ overstating Covid-19 vaccine effectiveness
The Texas attorney general has filed a lawsuit accusing Pfizer of “unlawfully” and “intentionally” misrepresenting…
Takeda, Janssen join wearable maker to measure scratching, and other health tech news
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology…
Do GLP-1s have a future treating alcoholism?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biden defends Trump-era drug pricing rule on copay accumulators
WASHINGTON — The Biden administration is appealing a court ruling against a Trump-era regulation that…
STAT+: FDA chief scientist to replace Woodcock
WASHINGTON — The Food and Drug Administration’s chief scientist will replace retiring Janet Woodcock as principal…
Flagship Pioneering crosses the pond, opens a European front
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Blood cancers may arise from CAR-T cells, but experts think only in very rare cases
The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy…
STAT+: White House official dings Bristol-Myers Squibb for fighting off generic competition
WASHINGTON — A top White House official on Tuesday delivered a pointed attack at a…
STAT+: Scott Gottlieb, Trump FDA chief, questions whether there’s a Republican philosophy on health care
WASHINGTON — One of the Republican party’s most prominent health care thinkers doesn’t know what…
STAT+: Biden invokes Cold War-era law to stem drug shortages
WASHINGTON — President Biden is using a Cold War-era law to stem drug shortages by…
STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma
The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which…
STAT+: Vertex pushes a donation program to widen access to cystic fibrosis treatments, but advocates say it’s not enough
Vertex Pharmaceuticals is being accused by a group of advocates and physicians of refusing to…
Today’s biotech news roundup, in under 800 words
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs
In response to strained budgets, a growing number of state and local governments across the…
STAT+: Most clinical trials run in Canada failed to take basic steps toward transparency, analysis finds
Just 3% of more than 3,700 studies run exclusively in Canada over a recent 10-year…
A new algorithm unveils CRISPR ‘treasure trove’
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: With new trial data, a blockbuster therapy from Sanofi, Regeneron could find an even bigger market
LONDON — The inflammation-targeting therapy Dupixent succeeded in a Phase 3 trial in patients with…
Medtronic isn’t afraid of Wegovy’s potential to disrupt
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Prominent pharmaceutical industry ally Anna Eshoo to retire
WASHINGTON — Rep. Anna Eshoo, one of the House of Representatives’ top Democrats on health…
STAT+: Sen. Bernie Sanders publicly pressures Merck, J&J, and Bristol Myers Squibb to testify on drug pricing
WASHINGTON — Senate Democrats, led by Sen. Bernie Sanders (I-Vt.) on Tuesday mounted a public…
Bayer’s new CEO was dealt a duo of ‘clearing events.’ Tough choices lie ahead
Want to stay on top of the science and politics driving biotech today? Sign up to get…